U.S. Markets closed

Nymox Pharmaceutical Corporation (NYMX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.10-0.07 (-1.68%)
At close: 4:00PM EDT

4.10 0.00 (0.00%)
After hours: 5:03PM EDT

People also watch
SPHSEBIOPBMDCYCCNVGN
Full screen
Previous Close4.17
Open4.17
Bid3.75 x 6000
Ask4.50 x 1500
Day's Range3.97 - 4.25
52 Week Range1.62 - 5.79
Volume139,707
Avg. Volume297,629
Market Cap206.84M
Beta1.34
PE Ratio (TTM)-15.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cubelast month

    Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Nymox Pharmaceutical Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Nymox Pharmaceutical Corp. – Abbott Laboratories, Eli Lilly and Company, Quest Diagnostics Incorporated, Pfizer Inc., Johnson & Johnson and Sophiris Bio Inc. (ABT-US, LLY-US, DGX-US, PFE-US, JNJ-US and ... Read more (Read more...)

  • Associated Presslast month

    Nymox reports 1Q loss

    On a per-share basis, the Nassau, Bahamas-based company said it had a loss of 6 cents. The biopharmaceutical company posted revenue of $78,400 in the period. Its adjusted revenue was $78,000. The company's ...

  • Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
    Capital Cube3 months ago

    Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Nymox Pharmaceutical Corp. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.04 million, Net Earnings of USD -2.83 million. Gross margins narrowed from 20.61% to 8.19% compared to the same period last year, operating (EBITDA) margins now -6,892.99% from -5,382.07%. Change in operating ... Read more (Read more...)